Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of mirikizumab in digestive organ disease (Japan)
jRCT2080225179Phase 3Recruiting
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3 trial of mirikizumab in gastrointestinal conditions (2 arms). Started Apr 2020; status: recruiting.
02
Drugs
mirikizumab
03
Conditions
gastrointestinal conditions
Beyond the preview
Go deeper on jRCT2080225179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225179.